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Abstract 
Malaria is currently treated with artemisinin (AN), a drug extracted from the plant 
Artemisia annua L.. Although many AN based combination therapies (ACTs) have long been 
effective in treating malaria, recent studies have suggested that the orally delivered dried leaves 
of the whole plant (pACT) also contain flavonoids that work synergistically with AN. Thus, 
pACT has recently been proposed as an effective and more affordable alternative for malaria 
treatment.  
In this study, this treatment was investigated by examining the effect of flavonoids on 
AN bioavailability. This was studied by examining the transport of AN alone and in conjunction 
with quercetin (Q) or rutin (R) across Caco-2 cell monolayers grown on 12-well permeable cell 
culture inserts. The Caco-2 cell monolayers were used to simulate the intestinal epithelium, thus 
providing a model for drug transport within the human body. To ensure that the monolayers were 
confluent enough to use in drug transport experiments and that they would not be damaged by 
the ethanol present in the apical solutions, representative monolayers were tested under 
controlled conditions using a Lucifer Yellow (LY) assay. The LY assays resulted in percent LY 
rejection values of greater than 75%, so the remaining monolayers were deemed confluent 
enough for the drug transport experiments. 
To determine the baseline for AN transport alone, apical to basolateral transport of AN 
was measured. To determine whether or not Q and R increased the transport rate or amount of 
AN across the monolayer, equimolar amounts of each flavonoid, in addition to AN, were added 
to the apical side of transwell inserts. The basolateral volumes were sampled every 15 minutes 
for one hour, extracted with methylene chloride and dried under N2 gas. AN was analyzed in the 
extracts by GC/MS and transport rates calculated ± Q and ± R.  This study demonstrated that, 
although both Q and R increased the rate of AN transport, only R increased the rate significantly. 
These findings may lead to a better understanding of the function of flavonoids in pACT. 
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1.0 Introduction 
Half of the world’s population is currently at risk of contracting malaria (WHO, 2013). 
Although malaria is a curable disease, most of the people who suffer from malaria do not have 
the resources to protect themselves from mosquitoes or obtain affordable health care. Because of 
the socioeconomic status of those at risk for malaria, the death toll is high. In 2010, an estimated 
655,000 people died of malaria (WHO, 2013). 
In spite of the global malaria eradication efforts that were undertaken by the World 
Health Organization (WHO) in the last century, many impoverished people in South America, 
Asia, and Africa still suffer from the ubiquitous transmission of malaria (CDC, 2012). Malaria 
endemic-societies are affected not only medically and emotionally by the disease, but are also 
impacted on a socioeconomic level. In 2012, the Centers for Disease Control and Prevention 
(CDC) estimated that at least 12 billion US dollars per year were spent worldwide on illness, 
treatment, and premature death due to malaria (CDC, 2012). Malaria therefore contributes to the 
cycle of poverty by depressing economic development, which in turn results in the delayed 
development of the necessary infrastructure for accessible healthcare. 
The WHO is currently using multiple approaches to address the malaria epidemic. 
Preventive interventions such as the use of insecticides and bed nets have been somewhat 
successful. However, once a person is infected, immediate treatment with antimalarial drugs 
offers the best chance at helping that person. Today, the WHO recommends a treatment called 
Artemisinin Combination Therapy (ACT) as the first-line drug treatment for uncomplicated P. 
falciparum malaria (WHO, 2013). ACT is highly effective, and it works by using AN, produced 
by the plant Artemisia annua, in combination with a partner drug to prevent AN drug resistance 
from emerging. However, for many of the people who suffer from malaria, ACT is unaffordable 
and inaccessible (Mutabingwa, 2005). 
Recent research about the possibility of an A. annua whole plant treatment (pACT) 
suggests that it may be a more effective and sustainable treatment for malaria than ACT 
(Weathers et al., 2010; Elfawal et al., 2012). Mouse studies showed that the dried plant delivers a 
larger amount of AN to the bloodstream than the pure drug (Weathers et al., 2010; Weathers et 
al., 2014a). Although the reason for this has not been determined, it is hypothesized that the 
increased bioavailability may be due to the other compounds, such as flavonoids, present in the 
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plant. Plant maturation and delivery methods can impact the amount of AN and flavonoids 
available in A. annua. In particular, AN increases as leaves mature. AN also increases during the 
process of drying and tableting for oral administration of pACT (Weathers and Towler 2014, 
unpublished). Such compounds could enhance the transport of AN across the intestinal cell 
epithelium. Additionally, although pACT is still being investigated, it has the potential to 
overcome some of the difficulties associated with the current antimalarial treatment options, such 
as affordability, accessibility, and drug resistance. 
In order to test the hypothesis that flavonoids present in the plant enhance the transport of 
AN, thereby increasing bioavailability of AN on the basolateral, or serosal, side of the 
monolayer, this project used a Caco-2 monolayer to study drug transport across the intestinal 
epithelium. Enhanced bioavailability was demonstrated, which further supports the argument that 
pACT is a more effective treatment for malaria than the currently established, but unaffordable, 
treatment options. 
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2.0 Literature Review 
2.1 Malaria 
Malaria is a highly infectious, mosquito-borne disease that is prevalent in South America, 
Asia, and Africa. The tropical and subtropical environments that are found on these continents 
are the perfect breeding ground for the Anopheles mosquito, which is capable of transmitting 
malaria to a human from a single bite (Barry, 2010). Malaria is most common in low-income 
developing countries, where people do not have the resources to protect themselves from 
mosquitoes (WHO, 2012). Although the number of deaths attributed to malaria has decreased 
from 2002 to 2012 due to drug treatments (such as ACT), vector control, insecticides, and the 
distribution of mosquito nets, > 500,000 deaths still occur each year (WHO, 2012). 
2.1.1 Biology 
Malaria is a blood disease caused by five different parasite species—Plasmodium 
falciparum, P. vivax, P. ovale, P. malariae, and P. knowlesi. The life cycle of the malaria 
parasite begins in a human when an infected mosquito transmits malaria sporozoites through a 
bite (Fig. 1; Lawrence Berkley Laboratory, 2001).  
The sporozoites then travel to and subsequently enter liver cells, and multiply thousands 
of times before bursting from the liver and entering the red blood cells in the blood stream. 
Within the first 48 hours of infecting a red blood cell, the malaria parasite undergoes several 
stages of development. In the first stage, “ring stage,” the parasite begins to ingest the contents of 
the infected cell (Barry, 2010). The next developmental stage is the trophozoite stage, during 
which the parasite continues metabolizing hemoglobin, grows larger, and prepares to reproduce. 
In the final stage, the parasite divides to form a multinucleated schizont. At the end of this cycle, 
the red blood cell ruptures and the parasites are disseminated to infect more red blood cells 
(Lawrence Berkley Laboratory, 2001; Fig. 1). 
Of all the strains, P. falciparum most often causes critical and life-threatening malaria 
(CDC, 2013). P. falciparum multiplies extremely rapidly in the blood and changes the adhesive 
properties of the red blood cells it inhabits. This change causes the red blood cells to stick to the 
walls of blood vessels resulting in severe blood loss and anemia (Lawrence Berkley Laboratory, 
2001;CDC, 2012). 
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Figure 1: Life cycle of malaria parasite (CDC, 2012) 
Although P.  falciparum is the most dangerous, all strains have their own risks. For 
example, P. vivax and P. ovale have dormant liver stages that can activate suddenly and invade 
the blood, effectively causing the human host to relapse, several months or years after the 
infecting mosquito bite (CDC, 2012). Additionally, P. malariae causes a long-lasting, chronic 
infection that in some cases can last a lifetime if it is untreated.  
2.1.2 Signs and Symptoms 
The symptoms caused by the five strains of malaria are similar. In most patients, the first 
symptoms will be felt 10 days to 4 weeks after infection. The initial symptoms are flu-like; fever, 
chills, headaches, muscle aches, and fatigue are common. However, if the disease is untreated, 
the symptoms may become more serious, including vomiting, diarrhea, anemia, jaundice, kidney 
failure, seizures, mental confusion, coma, and death (CDC, 2012). Because the symptoms can 
become so severe, it is imperative that patients with malaria seek immediate treatment. However, 
the availability of medical care depends on the geographical location and socioeconomic status 
of the patient in question. 
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2.1.3 Demographics 
Several factors, such as age, gender, geographical location, socioeconomic status, 
regional government, and availability of health care, determine whether or not a person contracts 
malaria. The two primary determining factors for risk of malaria transmission that will be the 
focus of this paper are geographical location and socioeconomic status, because these factors are 
arguably the largest determining factors of malaria risk. For example, the 2010 World Malaria 
Report stated that in 2010, of the 655,000 estimated deaths, the majority of which were children, 
91% were in Africa (WHO, 2010). This illustrates the importance of geographical location. Prior 
studies also highlighted the importance of socioeconomic status as a risk factor for malaria 
(Sachs & Malaney, 2002; Stratton et al., 2008). 
2.1.3.1 Geographical Location 
Climatic factors such as temperature, humidity, and rainfall often determine where 
malaria transmission occurs in the world (Hay et al., 2004). These factors must be ideal for the 
Anopheles mosquito to survive and reproduce, and for the parasite to complete its growth in 
Anopheles before it can be transmitted. At temperatures below 20°C, P. falciparum cannot 
complete its growth cycle in the mosquito, and thus cannot be transmitted to human hosts (CDC, 
2012). Because of this temperature constraint, P. falciparum is very common in many countries 
in Africa south of the Sahara desert. Of the human population at risk of contracting malaria via 
P. falciparum infection, 75% live in ten countries: India, China, Indonesia, Bangladesh, Pakistan, 
Nigeria, Vietnam, Thailand, Democratic Republic of the Congo and the Philippines (Guerra et 
al., 2006). 
Malaria is commonly transmitted in the tropical and subtropical areas of Africa, Asia, and 
South America (Figure 2), where the climatic factors are ideal for the survival of the Anopheles 
mosquito and the transmission of the malaria parasites into human hosts (CDC, 2012). Due to a 
cooler climate, economic development, and successful public health initiatives, citizens of 
Western Europe and the United States do not commonly suffer from malaria. The presence of the 
Anopheles mosquito in these countries, however, as well as global warming, indicate that citizens 
are at a constant risk of the disease being reintroduced into these areas (CDC, 2012). 
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Figure 2: A world map showing the prevalence of malaria transmission by geographical region 
(CDC, 2012). 
2.1.3.2 Socioeconomic Status  
Malaria is prevalent in some of the poorest areas of the world, and the costs associated 
with ubiquitous malaria transmission further depress economic development, which leads to an 
inability to pay for healthcare or preventative measures for malaria (such as insecticides or bed 
nets). The constant transmission of malaria in endemic African countries diminished annual 
economic growth by >1% per person from 1965 to 1990 (Sachs & Malaney, 2002).  
In 2012, the Centers for Disease Control and Prevention (CDC) estimated the direct costs 
of malaria for the world and that at least 12 billion USD per year were spent worldwide on 
illness, treatment, and premature death due to malaria. The CDC also stated, “costs are many 
times more than that in lost economic growth,” (CDC, 2012). Therefore, malaria contributes to 
the cycle of poverty in poor and underdeveloped areas.  
2.1.4 Eradication Efforts 
In the past, many efforts were made to eradicate malaria. Insecticides, political and social 
mobilization efforts, and environmental modifications (such as destroying the habitat of the 
Anopheles mosquito or distributing bed nets) were used (CDC, 2012). However, all of those 
efforts were preventive interventions, and did not help those already suffering from the disease.  
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Because malaria can be severe, immediate treatment of infected patients with antimalarial drugs 
offers the best chance at helping those patients and their surrounding community.  
The successful use of drugs and preventive interventions, including the widespread use of 
DDT, resulted in the eradication of malaria in the United States and Western Europe in the mid-
1900s (Harrison, 1978). This was likely because these areas have cooler climates and more 
developed infrastructures than the areas currently plagued by malaria. Despite success in the 
United States and Europe, worldwide eradication of malaria largely failed. Malaria continues to 
be a major health issue for many people in Africa, Asia, and South America today. In fact, more 
people are killed by malaria currently than 40 years ago (Stratton et al., 2008). This indicates that 
new strategies are needed to control the transmission of the disease. 
2.2 Artemisinin 
In the 1970’s, scientists noticed that protozoans of the genus Plasmodium were gaining 
resistance to the anti-malarial drugs that were on the market. Research into a new treatment with 
the herb Artemisia annua L. began. A. annua prepared as a tea infusion was used as a remedy for 
fevers in China for >2,000 years (Kew Royal Botanical Gardens, 2013). In 1972, it was found 
that the plant contained a metabolite that exhibited antimalarial properties. This compound was 
identified as AN (Tu, 2011; Fig. 3) 
2.2.1 Classification of Artemisinin 
There are two kinds of plant metabolites, primary and secondary. Primary metabolites 
play a role in the basic life function of plants. They are used in processes like respiration, growth, 
cell division and reproduction. Secondary metabolites serve many purposes including 
pigmentation, ultraviolet protection and defense. (Bourgard et al., 2001) The three major groups 
of secondary metabolites are: phenolics, nitrogenous compounds and terpenes. (Taiz and Zeiger, 
2010). Certain secondary metabolites have antibiotic, antiviral and antifungal properties. AN is a 
secondary plant metabolite with antimicrobial properties.  
AN’s chemical structure (Figure 3) is classified as a sesquiterpene lactone endoperoxide 
(Brisibe, 2008). Terpenes are naturally made compounds with a ratio of five carbons to eight 
hydrogens, they are given a prefix based on the number of 5-C isoprene units contained in the 
compound. The first part of AN’s structural name, “sesquiterpene,” refers to a terpene with 15 
carbons, 3 isoprene units. 
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        A B                        
C D  
Figure 3: Structure of artemisinin (A), artemether (B), artesunate (C) and artemotil (D) 
(Wikimedia, 2011a, 2007a, 2007b, 2007c) 
The second word describing AN’s structure, “lactone” refers to a cyclic compound containing a 
carbonyl and an ether group.  An endoperoxide is a compound containing a single bond between 
two oxygens located within a ring (Wade, 2010). In AN, the endoperoxide is believed to be 
responsible for the mechanism of action that causes the compound to be antimalarial (Meshnick, 
2002).  
2.2.2 Glandular Trichomes 
AN is synthesized, secreted and stored by glandular trichomes on the leaves of A. annua. 
Glandular trichomes are protrusions that grow on specialized epidermal cells located on the 
leaves or other organs of a plant. The number of glandular trichomes on the surface of A. annua 
leaves increases from the third month to the flowering stage of plant development (Guo et al., 
2012). Once the plant reaches flowering, the density of glandular trichomes stops increasing. 
This is why dried leaves used for malaria treatment are harvested just before flowering (Guo et 
al., 2012). Other compounds secreted by the glandular trichomes include essential oils, 
phenolics, flavonoids and terpenoids (Wu et al., 2012).  
The importance of AN as an antimalarial drug has led to studies of these trichomes. On 
average AN only makes up 0.01 – 1.1% of the dry weight of A. annua (Guo et al., 2012); 
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increasing this percentage would allow the drug to be more widely used. Efforts in this direction 
include the identification of intermediate compounds engaged in AN production and the cloning 
of enzymes involved in the AN biosynthesis pathway (Guo et al., 2012).  
2.2.3 Artemisinins and ACTs as Treatment for Malaria 
Artemisinins are chemically modified versions of AN extracted from the plant, Artemisia 
annua L. (CDC, 2012). Artesunate is one such AN derivative (Figure 3).  In 2007, the Food and 
Drug Administration (FDA) approved an investigational new drug protocol called “Intravenous 
Artesunate for Treatment of Severe Malaria in the United States.” This allowed artemisinins to 
be available as an antimalarial treatment in the United States for the first time (CDC, 2012). 
Currently, artesunate can be obtained from the CDC for use in treating severe malaria with either 
an inability to take oral medications or an inability to quickly and safely take intravenous 
quinidine (CDC, 2012). 
Artemisinin-based combination therapies (ACTs) combine an AN derivative with a 
partner drug (Rosenthal, 2008). ACT contains at least two antimalarials within one pill. One of 
these antimalarials is AN-based, meaning that it is a derivative of AN. The three AN derivatives 
are: artesunate, artemether and artemotil (Figure 3). Currently, these derivatives may be 
combined with lumefantrine, amodiqine, mefloquine, sulfadoxine-pyrimethamine, piperaquine or 
pyronaridine tetraphosphate within an antimalarial pill (World Health Organization, 2012). For 
example, the drug Coartem® is a combination of the AN deriviative artemether and the synthetic 
drug lumefantrine (CDC, 2012). This provides a more effective treatment than treating malaria 
with pure AN, because some species of the Plasmodium parasite may have evolved AN-
resistance (WHO, 2013). Thus, the use of ACTs is purported to prevent or slow the evolution of 
AN drug resistance (Bloland, 2001). ACT works by using the AN compound to reduce the main 
parasite load during the first three days of treatment, while the partner drug eliminates the 
remaining parasites that may survive due to AN resistance. Because of their efficacy, ACTs are 
recommended by the WHO as the first-line drug treatment for uncomplicated P. falciparum 
malaria (WHO, 2013). 
2.2.4 An Alternative Artemisinin Combination Therapy 
Recent research by Elfawal et al. (2012) using P. chabaudi-infected mice suggested that 
orally administered dried leaves of A. annua may be more effective at curing the disease than 
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purified AN. This whole plant treatment is referred to as plant Artemisinin Combination Therapy 
(pACT). Using the rodent malaria model, Plasmodium chabaudi, infected mice were 
administered a single dose (24 mg AN/kg mouse body weight) of whole plant A. annua, a single 
dose of pure AN (24 mg AN/kg mouse body weight) or a placebo (mouse chow without drug). 
Mice treated with low-dose whole plant had significantly lower parasitemia than the pure AN 
treated mice up to 72 hours post treatment. (Elfawal et al., 2012).  
In another study conducted by Weathers et al. (2010), the bioavailability, or the rate at 
which a substance enters the bloodstream, of pure AN was compared to the bioavailability of 
pACT. When pACT containing 30.7 µg of AN was administered to the mice, a concentration of 
0.087 mg L-1 was found after only thirty minutes. When pure AN containing 30.7 µg was 
administered, the drug remained undetectable in the bloodstream 60 minutes after consumption. 
Eventually, after administering 1,400 µg of pure AN to the mice, the blood concentration 
reached 0.074 mg L-1. These results suggested that the AN contained in A. annua was 45-fold 
more bioavailable than pure AN. A more recent pharmacokinetic study by Weathers et al. 
(2014a) showed that the presence of plant material was crucial for movement of large amounts of 
ANinto the serum. 
Few studies have been done on the effect of pACT in humans. Mueller et al. (2000) 
treated P. falciparum infected adults with A. annua tea. Despite some success at the beginning of 
the therapeutic tea trials, after a short period of parasitic inactivity, the P. falciparum reemerged 
(Mueller et al., 2004). These trials suggest that A. annua tea, as a therapeutic for malaria, is not a 
viable option. This is partially due to the difficulty controlling the AN dose in the tea (Weathers 
et al., 2014c). Another study conducted by the International Centre of Insect Physiology and 
Ecology (ICIPE) and Kenya Medical Research Institute (KEMRI) showed that 80-91% of the 48 
patients treated with varying doses of AN in the form of tableted A. annua plant material did not 
exhibit recrudescence (ICIPE, 2005). A similar study in Bangui, Central Africa found that 
administration of whole plant therapy capsules containing 0.4-0.5 mg of AN reduced parasitemia 
by 62% in a group of 25 patients, 22 of whom were children (Onimus et al., 2013). These studies 
indicated that A. annua has the possibility of being an effective AN combination therapy. 
However more studies of how other compounds in A. annua affect AN content are necessary. 
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2.2.5 Compounds to Investigate 
Flavonoids contain aromatic hydrocarbons bonded to a hydroxyl group. Flavonoids are 
often the pigments in flowers that act as attractants for pollinators, and in fruit for seed dispersal. 
Flavonoids have antioxidant activity, because they are capable of reacting with and detoxifying 
free radicals (Pietta, 2000). Many are also antimalarial. In a study by Lehane and Saliba (2008), 
eleven flavonoids were tested for antiplasmodial activity. Each of the eleven flavonoids showed 
activity against a chloroquine-resistant strain of P. falciparum with IC50 values between 12 and 
76 µm. Liu et al. (1992) also demonstrated that flavonoids have anti-plasmodial activity. A 
chloroform extract of A. annua cells, in which no artemisinin was detected, was found to have an 
IC50 of 14.5µg/mL. The extract contained methoxylated flavonoids including artemetin, 
chrysoplenetin, chrysoplenol-D and cirsilineol (Liu et al., 1992). Casticin was not detected in the 
chloroform extract; however, Elford et al. (1987) showed that casticin in combination with 
artemisinin assisted in the inhibition of P. falciparum growth. Artemetin was less effective in 
combination with artemisinin but still showed a synergistic effect. This effect was only 
demonstrated when the flavonoids were combined with artemisinin and did not appear when 
combined with another anti-malarial, chloroquine. Table 1 shows the IC50 values of flavonoids 
found in A. annua. 
Table 1: Flavonoids in A. annua and their IC50 values against P. falciparum 
Flavonoids IC50 Values (uM) Reference 
Artemetin 26 Liu et al. (1992) 
 
Casticin 24 Elford et al. (1987) 
Chrysoplenetin 23  
Liu et al. (1992) Chrysoplenol-D 32 
Cirsilineol 36 
Kaemferol 25 ± 2  
Lehane & Saliba (2008) Luteolin 12 ± 1 
Myrectin 76 ± 23 
Quercetin 14 ± 1 
Rutin 7 ± 10 Ganesh et al. (2012) 
 
 It may be that in A. annua the flavonoids and AN work in harmony to destroy the parasite, 
which may explain why pACT is effective (Kim et al., 2007).  
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For this project, the flavonoids quercetin (Q) and rutin (R) will be studied (Figure 4); R is 
the glycoside of Q, containing the two rutinose sugars, rhamnose and glucose. R is water soluble 
and converted into Q when it enters the blood stream (Erlund et al., 2000). Both R and Q are 
polyphenolic compounds that are found in fruits, vegetables, leaves, herbs, seeds, red wine, 
coffee, beer and tea (Azevedo et al., 2013). 
A   B  
Figure 4: Structure of quercetin (A) and rutin (B) (Wikimedia, 2013, 2009) 
 In a study by Ganesh et al. (2012), both R and Q inhibited field isolated and lab-adapted 
P. falciparum. R had an IC50 that was about half that of Q for the field isolates, showing that R 
had a greater inhibitory effect on the parasite (Table 1). For one of the two lab-adapted clones of 
P. falciparum, R and Q had IC50 values that were statistically the same. For the second lab-
adapted clone, R had a higher IC50. This showed that even though both R and Q have anti-
plasmodial activity, the extent of this activity may differ depending on the malaria-causing agent, 
the bioavailability of R and Q post-digestion, and/or the pathways of transport for Q and R. Q is 
transported via the passive transcellular pathway, while R is transported using active carrier-
mediated transport (Walgren et al., 1998). This may be due to the glycosidic nature of R 
(Hollman et al., 1999).  
2.2.6 Prior Work 
To quantify the AN and flavonoid content, after digestion but before adsorption into the 
bloodstream, a simulated digestion study was conducted using A. annua dried leaves (Weathers 
et al., 2014b). This study simulated the oral, gastric and intestinal phases of digestion. Table 2 
shows how each phase of digestion was simulated. 
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Table 2: Methods used to simulate digestions of A. annua dried leaves 
Digestion Phase Method of Simulation 
Oral 1. 1. Vortex solution of  0.36 AN, 1.64 mL H2  
2. Blanket solution with N2 and cap 
3. Place solution in 37° water bath for 10 minutes 
Gastric 1. Place solution on ice 
2. Add saline and adjust the pH to 4.0 with HCl 
3. Blanket solution with N2 and cap 
4. Incubate for 60 min. at 90 opm 
Intestinal 1. Place solution on ice 
2. Adjust pH to 4.0 with NaHCO3  
3. Add 0.5 mL NaHCO3 and 0.75 mL bile extract 
4. Adjust pH to 6.5, add saline and blanket with N2 
5. Place test tube in 37° water bath and incubate at 90 opm for 2 hours 
The study examined how the leaves of A. annua digested with various food sources affected the 
bioavailability of AN and flavonoid content in the intestinal liquid. First the dried leaves were 
digested alone and AN and flavonoid levels were measured. Table 4 shows the results from this 
study. Undigested dried leaves contained approximately 7.6 mg/g DW of AN and about 2.9 mg/g 
DW of flavonoids. The AN and flavonoids recovered after each phase of digestion were less than 
the starting material. AN is assumed to be most bioavailable once it is released into the liquid of 
each digestion phase; only 22% of the starting AN was found in this phase (Weathers et al., 
2014b; Table 3). 
Table 3: Results from A. annua dried leaves digestion simulation (Weathers et al., 2014b) 
Digested Leaves Artemisinin Content  
(mg/g DW) 
Flavonoids  
(mg/g DW) 
 Solid Phase Liquid Phase Solid Phase Liquid Phase 
Oral Phase 5.46 0.61 1.158 0.071 
Gastric Phase 5.55 0.81 0.899 0.064 
Intestinal Phase 2.24 1.72 0.983 0.087 
Dietary components were then added to the dried leaves prior to digestion. The 
components tested and their relative impacts on AN and flavonoid level extracted from the 
intestinal phase of digestion are shown in Table 4. When dried leaves were combined with 
sucrose, canola oil, peanut oil or white rice the release of AN was not negatively affected. In 
addition, when dried leaves were combined with many of the dietary components the available 
flavonoid content in the intestinal liquid increased significantly. For sucrose and canola oil, the 
dried leaves contained 0.10 mg FLVs/g DW, whereas the sucrose and canola oil combined with 
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dried leaves contained <0.20 mg FLVs/g DW. Digestion in the presence of millet, cornmeal, 
however, reduced AN release into the liquid phase of the intestinal stage of digestion.  
Table 4: Dietary components added to dried leaves and their effects on AN and flavonoid content 
Dietary Component Percent change from dried leaves digested alone 
 Artemisinin (%) Flavonoids (%) 
Sucrose -8a +105 
Canola oil -19a +101 
Red palm oil -35a +99 
Sunflower oil -41a +132 
Peanut oil -6a +59 
White rice meal -21a +54 
Corn meal -58b +103 
Millet Meal -42b +15 
Weathers et al. (2014b) further showed that, when digested, therapeutic compounds from dried 
leaves would likely be more bioavailable if administered as a tablet rather than in a capsule 
because both gelatin and cellulose capsules reduced AN availability. The next step in 
determining bioavailability of AN and flavonoids in A. annua is to determine the rate at which 
these compounds move across the intestinal epithelium. In studying the transport of these 
compounds in vitro, the Caco-2 cell line is often used. 
2.3 Caco-2 Cells 
The Caco-2 (ATCC® HTB37™) cell line is a line of human colorectal adenocarcinoma 
cells originally isolated from a Caucasian male, aged 72 years. Although there are many human 
colorectal adenocarcinoma cell lines, only two lines are closely related, in terms of structure and 
function, to the Caco-2 cell line. The HT-29 (ATCC® HTB-38™) line is a tumorigenic line 
derived from a Caucasian female aged 44 years, whereas the C2BBe1 [clone of Caco2] (ATCC® 
CRL2102™) cell line is a clonal line derived from Caco-2 cells. Though similar in function, 
neither HT-29 nor C2BBe1 express receptors and genes identical to Caco-2. These differences in 
protein expression cause physical differences, such as the multilayered monolayers that can be 
seen in HT-29 cultures (ATCC, 2012a; ATCC, 2012c). This makes HT-29 and CBBe1 
unsuitable for use as a model system. 
2.3.1 Characteristics and variability  
The Caco-2 cell line (HTB-37) is characterized by epithelial-like morphology, with 
generally polygonal shape and adherent growth. (ATCC, 2012b, Figure 5). This adherent growth 
allows Caco-2 cells to form a confluent monolayer with tight intercellular junctions. Exponential 
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cell growth slows to a consistent, linear rate after approximately six days (Hidalgo et al., 1989). 
Upon reaching confluence, Caco-2 cells in culture differentiate into a monolayer that is polarized 
apically and basolaterally. These cells have a similar structure and function to that of enterocytes, 
which are the epithelial cells that line the intestines, making Caco-2 cells a good model for study 
of drug transport from the intestine into the blood stream. 
 
Figure 5: Caco-2 cells in a confluent monolayer 
Differentiated Caco-2 cells are characterized by the expression of heat stable enterotoxin, 
epidermal growth factor, and retinoic binding proteins I and II (Sun and Pang, 2008). 
Additionally, cell morphology is more similar to that of enterocytes, including the growth of 
microvilli (Hidalgo et al., 1989). To maintain a consistent expression of enterocytic structure and 
function, regular quality control must be conducted on the cultures (Hubatsch et al., 2007). 
Without proper quality control, the Caco-2 cell line, with multiple passages may alter 
over time. Quality control is crucial to prevent the integrity of the cell monolayer from declining, 
which means that the cells would no longer form the tight intercellular junctions that make Caco-
2 cells useful as a model system for the human intestine. After 70 passages, there is significant 
decline in membrane integrity (Briske-Anderson et al., 1996). For this reason, two primary 
quality control procedures exist to test the integrity of a Caco-2 monolayer: measurement of 
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trans-epithelial electrical resistance (TEER or TER), and diffusion of a known compound across 
the monolayer (Briske-Anderson et al., 1996). 
 TEER is a measurement of resistance of the cell monolayer to an electrical current. This 
is done using a TEER probe, which is attached to a voltmeter. To measure TEER, one probe is 
placed on the apical side of the monolayer, and a second probe is placed on the basolateral side 
of the monolayer. Using the reading on the voltmeter, the TEER can be calculated using the 
formula:  
 
𝑇𝐸𝐸𝑅 𝑣𝑎𝑙𝑢𝑒 (𝑜ℎ𝑚 ∙ 𝑐𝑚2) =  𝑇𝐸𝐸𝑅 𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑚𝑒𝑛𝑡 (𝑜ℎ𝑚𝑠) ∗ 𝐴𝑟𝑒𝑎 𝑜𝑓 𝑚𝑒𝑚𝑏𝑟𝑎𝑛𝑒 (𝑐𝑚2) 
  
If a TEER probe is not available, diffusion of a known compound across a Caco-2 
monolayer can instead be used by tracking a radioactive compound, such as [14C]mannitol, or a 
dye compound, such as Lucifer Yellow (Hubatsch et al., 2007; Himanshu, 2013). The integrity 
of the monolayer can be assessed by adding one of the above test compounds to the apical side of 
the monolayer and determining the permeability coefficient using the formula: 
 
𝑃𝑒𝑟𝑚𝑒𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 (𝑐𝑚 𝑠)⁄ =
∆𝑄
∆𝑡
∗
1
𝐴 ∗ 𝐶0
 
 
In this formula, 
∆𝑄
∆𝑡
 is the permeability rate, in µg/min, of a given compound, A is the surface area 
of the Caco-2 monolayer (cm2), and C0 is the initial concentration, in µg/mL, on the apical side 
of the monolayer (Augustijns et al., 1996). A permeability coefficient, Papp, of approximately 1.2 
nm/s indicates a monolayer that is sufficiently confluent and is ready to be used in experiments 
(Hubatsch et al., 2007).  
An alternative method for quality control using a dye compound is to measure the 
rejection, or lack of passage, of the compound through the Caco-2 monolayer. This is done by 
adding the fluorescent dye, Lucifer Yellow, on the apical side and measuring the relative 
fluorescence units (RFU) of the dye on the basolateral side. Percent rejection of Lucifer Yellow 
is assessed using the following formula: 
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% 𝐿𝑢𝑐𝑖𝑓𝑒𝑟 𝑌𝑒𝑙𝑙𝑜𝑤 𝑅𝑒𝑗𝑒𝑐𝑡𝑖𝑜𝑛
= 100 ∗ (1 −
𝑅𝐹𝑈 𝑜𝑓 𝐿𝑢𝑐𝑖𝑓𝑒𝑟 𝑌𝑒𝑙𝑙𝑜𝑤 𝑜𝑛 𝑏𝑎𝑠𝑜𝑙𝑎𝑡𝑒𝑟𝑎𝑙 𝑠𝑖𝑑𝑒
𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑅𝐹𝑈 𝑜𝑓 𝐿𝑢𝑐𝑖𝑓𝑒𝑟 𝑌𝑒𝑙𝑙𝑜𝑤 𝑎𝑑𝑑𝑒𝑑 𝑡𝑜 𝑎𝑝𝑖𝑐𝑎𝑙 𝑠𝑖𝑑𝑒
) 
 
The percent of Lucifer Yellow rejection should increase with culture time, as the Caco-2 
monolayers become more confluent (Corning Life Sciences Incorporated, 2013; Himanshu, 
2013). 
Although it is useful to implement both TEER measurement and transport of a known 
compound as quality control methods, it is not necessary. It has been shown that increased TEER 
corresponds to increased Lucifer Yellow rejection, and vice versa (Hidalgo et al., 1989). 
2.4 Drug Permeability and Transport Studies 
 The differentiation of Caco-2 cells into a functional enterocytic monolayer makes the 
Caco-2 cell line ideal for studies that require a model system that mimics the human intestinal 
epithelium. In particular, the Caco-2 monolayer can be used to study drug transport across the 
intestinal epithelium and thus predict drug absorption in humans (Artursson et al., 1996). The 
intestinal epithelium is the critical barrier to drug transport and absorption and, therefore, 
passage through the intestinal epithelium is the rate-limiting step in absorption of a drug 
(Hidalgo et al., 1989). 
2.4.1 Drug Transport Pathways 
There are four transport pathways across the intestinal epithelium: the passive 
transcellular pathway, the passive paracellular pathway, the active carrier-mediated transcellular 
pathway, and the transcytosis pathway (Artursson et al., 1996; Figure 6). In the passive 
transcellular pathway, indicated by arrow A in Figure 6, a given molecule passes through the 
semi-permeable membrane on the mucosal, or apical, side of a polarized enterocyte, passes 
through the cell, and passively diffuses across the cell membrane on the serosal, or basolateral 
side with no energy exerted by the cell. Similarly, in the passive paracellular pathway, B in 
Figure 6, a given molecule diffuses from mucosal to serosal side through the junction between 
two enterocytes. The third possible pathway, C in Figure 6, is the active, carrier-mediated 
pathway. Carrier-mediated transport involves a cellular carrier protein, a type of membrane 
transport protein, binding to the target molecule. The molecule-carrier complex then undergoes a 
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series of conformational changes in order to transfer the molecule across to the opposite 
membrane from which the molecule was accepted (Alberts et al., 2007, p. 653). The final 
pathway for transport across the intestinal epithelial membrane is the transcytosis pathway, D in 
Figure 6. In this pathway, specific molecules are recognized by receptors on the surface of the 
cell membrane, which then forms a vesicle around the molecule. This vesicle is then transported 
across the intracellular space until the vesicle fuses with the serosal-side membrane, releasing the 
molecule (Alberts et al., 2007, p. 797). 
 
Figure 6: Drug transport pathways 
Most drug compounds that are orally administered in humans are absorbed across the 
intestinal epithelium through the passive transcellular pathway (Fig. 6A; Artursson and Karlsson, 
1991). Additionally, drug compounds that are hydrophilic or peptide-based are likely to pass 
through the passive paracellular pathway or the carrier-mediated pathway, (Fig. 6B and C, 
respectively) if their shape resembles that of cell nutrients. However, AN is neither peptidic nor 
hydrophilic, it is likely to cross the intestinal epithelium through the passive transcellular 
pathway. This assumption was supported by a study of AN transport through Caco-2 monolayers 
(Augustijns et al., 1996). 
2.4.2 Transport of Artemisinin 
 To increase understanding of the oral absorption of AN and its more water-soluble 
analogue, sodium artesunate, a study of AN transport and absorption across Caco-2 monolaryers 
compared apical to basolateral (a  b) and basolateral to apical (b  a) transport of both 
compounds under different conditions (Augustijns et al., 1996).  The permeability of AN was 
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significantly higher than sodium artesunate, with permeability coefficients (Papp) of 30.4 and 4.0 
(x 10-6) cm sec-1, respectively (Table 5). Additionally, transport of AN across the Caco-2 
monolayer did not significantly differ between a  b and b  a direction; Papps were 30.4 and 
30.9 (x 10-6) cm sec-1, respectively. Thus, AN must cross the monolayer through the passive 
transcellular pathway, rather than through active transport. This is further supported by little to 
no change in AN permeability when the temperature was decreased from 37 to 2°C, and also in 
the presence of sodium azide (Table 5). An active transport mechanism would be more 
temperature-dependent and subject to azide poisoning (Augustijns et al., 1996). From these data, 
it was concluded that although AN has low solubility in water, it readily crosses the intestinal 
epithelium through passive diffusion (Augustijns et al., 1996). 
Table 5: Caco-2 permeability of AN under various conditions (Augustijns, 1996) 
Conditions T (°C) Papp (x10-6) (cm/s) SD 
Artemisinin (100 µM, 1 h) 
Apical to Basolateral Transport 
(a  b) 
37 30.4 1.7 
20 22.5 0.5 
2 20.0 0.5 
Basolateral to Apical Transport 
(b  a) 
37 30.9 2.6 
Sodium Azide (1 mM) 
(a  b) 
37 30.8 1.9 
Artesunate (10 mM, 1 h) 
pH 7.4 
(a  b) 
37 4.0 0.4 
2.4.3 Ethanol in Drug Transport Studies 
To effectively dissolve drug compounds for use in Caco-2 transport studies, the solubility of the 
drug compound must be evaluated. For compounds with low solubility in transport media, the 
use of organic solvents, such as ethanol, may be necessary. However, when using such solvents, 
it is important to note the potential for damage to the Caco-2 monolayers from extended 
exposure.  
In human mast cells, which, like Caco-2 cells, occur in the gastrointestinal tract, exposure 
to 43 mM of ethanol for a period of four days reduced cell viability by approximately 40% 
(Nurmi et al., 2009). In addition to inducing apoptosis, exposure to ethanol can reduce the rate of 
proliferation of cells in vitro. A study in the human promyelocytic leukemia cell line, HL-60, 
showed that cells cultured with 0.5-4% ethanol in culture media, had a significantly lower 
proliferative rate after 24 hours of culture. However, after only 1 hour of culture, the different 
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ethanol concentrations did not have statistically different effects on cell proliferation (Mareková 
et al., 2000). 
In studying drug transport across Caco-2 monolayers, an incubation of 1-2 hours is 
generally used (Hubatsch et al., 2007). Thus, the time in which the Caco-2 cells are exposed to a 
drug compound dissolved in ethanol is limited enough that massive apoptosis in the monolayer is 
unlikely. However, incubation with ethanol can cause morphological changes in the Caco-2 
monolayers, namely the reduction of monolayer confluence (Moyes et al., 2010). A study by 
Moyes et al. (2010) on the effects of culture conditions on particle uptake by Caco-2 monolayers 
showed that a treatment of 10% ethanol in culture medium for 60 minutes reduced trans-
epithelial resistance, a measure of monolayer confluence, by 23%. 
It is clear that a 60 minute exposure of Caco-2 cells to 10% ethanol is damaging to the 
cell monolayer and will therefore affect the results of drug transport studies. For that reason, all 
concentrations of ethanol used to dissolve hydrophobic (low-solubility) drug compounds should 
be less than 10%. At any concentration used, there must be a control for ethanol exposure. For 
this, one or more transwells should be exposed for the entirety of the study to ethanol and 
transport medium, at the percentage of ethanol used for the actual transport experiment, after 
which the monolayer integrity should be evaluated. If needed, such a control could then be used 
to normalize the data collected from the drug transport studies to account for any drug transport 
that results from decreased monolayer integrity, rather than true transport across the Caco-2 
monolayers.  
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3.0 Hypothesis 
By using a Caco-2 monolayer to simulate drug transport across the intestinal epithelium, 
this study will establish the effect of Q and R on the transport of AN across the Caco-2 
monolayer. If addition of either or both of compounds increase the Papp of AN, this would 
indicate that Q and/or R increase the bioavailability of AN on the serosal side of the monolayer. 
Objectives: 
1. Establish the model system for studying the transport of secondary plant metabolites 
across a Caco-2 monolayer. 
2. Measure the transport of AN passage through a Caco-2 monolayer to replicate the study 
by Augustijns et al. (1996).  
3. Measure the transport of AN + Q through a Caco-2 monolayer. 
4. Measure the transport of AN + R through a Caco-2 monolayer. 
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4.0 Methodology 
4.1 Cell Line & Maintenance 
Human epithelial colorectal adenocarcinoma cell line, Caco-2 (HTB-37), was obtained 
from the American Type Culture Collection (ATCC). The culture conditions recommended by 
the ATCC were ambient air with 5% carbon dioxide at 37° C. The complete growth medium as 
recommended by the ATCC was Eagle’s Minimum Essential Medium (EMEM) with 20% fetal 
bovine serum (FBS). Cells cultured in either 25 or 75 cm2 T-flasks were maintained in EMEM 
with 20% FBS and 1% penicillin/streptomycin. Under these culture conditions, the population 
doubling time for Caco-2 cells is approximately 62 hours (American Type Culture Collection 
(ATCC), 2012b). Cells seeded onto transwell inserts were maintained in 10% FBS with 1% 
penicillin/streptomycin to promote differentiation. All cultures were fed and passaged as needed. 
4.2 Creation of drug transport study model system using Caco-2 Monolayers 
The permeability and absorption experimental setup of this study used the protocol 
described by Hubatsch et al. (2007). The Caco-2 cells were cultured on 12 mm semi-permeable 
polycarbonate transwell inserts that have a 0.4 µm pore size. Cells were seeded onto transwell 
inserts approximately three weeks before the experiment to allow the cells time to differentiate 
into confluent monolayers on the membrane.  
For inoculation of transwells inserts, confluent Caco-2 cultures grown in 25 or 75 cm2 T-
flasks were first trypsinized. Cell culture medium was removed by aspiration. Cells were rinsed 
with Phosphate Buffered Saline (PBS). PBS was aspirated and a trypsin solution composed of 
80% PBS, 10% edetic acid and 10% trypsin (10 x stock solution 2.5% (wt/vol)) was added. 
During trypsinization, cells were scraped off the culture surface with a cell scraper. The protease 
activity of trypsin, in combination with cell scraping, served to detach cells from the culture 
surface and one another. Once this is accomplished, the protease activity of trypsin was stopped 
by diluting the trypsin with culture medium (EMEM). 
The cell suspension was then transferred to a 15 mL conical tube. The conical tube was 
centrifuged at 100 x g for three minutes, causing a pellet of cells to form at the bottom of the 
tube. After centrifugation, the supernatant in the tube was aspirated and the cell pellet 
resuspended in culture medium (EMEM). A 0.1 mL sample of the cell suspension was taken to 
count viable cells.  An aliquot of 0.1 mL of 4% solution of trypan blue was added to the sample, 
which was then pipetted into a hemocytometer. When viewed under a microscope, cells that have 
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turned blue were not considered viable. To continue with the experiment, at least 95% of the 
cells must be viable (Strober, 2001). 
At this point, a hanging transwell insert of 1.92 cm2 area (Corning Inc., Product #3401) 
was placed in each well of a 12-well, culture plate (Corning Inc., Product #3513), wetted with 
0.1 mL of EMEM and left for two minutes. The cells were then seeded by pipetting the 
necessary volume of cell suspension to achieve 300,000 live cells onto each transwell insert. 
Culture medium was added to bring the volume to 0.5 mL. Immediately afterwards, the 
basolateral chamber was filled with 1.5 mL of culture medium and the well plates were 
incubated at 37°C for three weeks. Every third day during this period, the medium from both the 
basolateral and apical sides was aspirated and replaced with 0.5 mL and 1.5 mL of EMEM, 
respectively. 
Before drug transport studies were performed, a confluence check was completed using 
the standard operating procedure for Lucifer Yellow assays as detailed in Appendix B. If the 
Lucifer Yellow assay resulted in a Lucifer Yellow rejection of approximately 80% or greater, the 
Caco-2 monolayers were considered sufficiently confluent for use in drug transport studies. For 
drug transport studies, the solution to be placed on the apical side was warmed to 37°C. This 
solution was composed of phosphate buffered saline (PBS) and certain dissolved compounds, 
depending on the particular experiment. The compounds may be AN, FLVs, or a combination of 
these. When the solutions were prepared, the transwell inserts were transferred to new 12-well 
plates containing PBS on the basolateral side and 0.5 mL of PBS + compound solution added to 
the apical side of the monolayer. A zero time sample was taken from the solution on the apical 
side. The well plates were then incubated at 37°C for 60 minutes. At 15 minute intervals, the 
transwell inserts were transferred to new well plates containing 1.5 mL fresh PBS on the 
basolateral side. The media remaining in each well plate was extracted. A final sample was also 
taken from the apical chamber at 60 minutes. 
4.3 Transport of test compounds across a Caco-2 monolayer 
 To measure the amount of AN that passes through a Caco-2 monolayer, apical to 
basolateral transport experiments were performed as described by Hubatsch, et al. (2007) and 
modified to suit the transport of AN. To maintain sink conditions, meaning that concentration of 
compound on the basolateral side does not exceed 10% of that of the apical side, during the 
transport experiment, the transwell inserts were transferred to fresh 12-well plates containing 
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PBS every fifteen minutes for one hour, as suggested by Augustijns, et al. (1996) and Hubatsch 
et al. (2007). Because the transwell inserts were transferred to new well plates every fifteen 
minutes for one hour, the  basolateral medium in the used well plates was extracted for 
quantification of AN by Gas Chromatography – Mass Spectrometry (GC/MS). 
Table 6 describes the experimental set-up for transport of AN ± Q or R. All stock 
solutions of AN, Q and R were made in 70% ethanol. For the AN studies, a small aliquot of 70% 
ethanol was added to maintain a constant volume of ethanol throughout all studies. The AN stock 
solution was 7.08 mM to yield 177.09 µM of AN in each transwell, as described in Table 6. 
Table 6: Experimental design for apical transport media 
Experimental 
Treatment 
Volumes for Transport 
Medium (µL) 
Amount of Compound per 
Transwell (µg) 
Concentration 
of Compound 
per Transwell 
(µM) 
Stock 
Solution 
70% 
Ethanol 
PBS 
AN 12.5 AN 12.5 475 25 AN 177.09 AN 
AN + Q 12.5 AN 0 475 25 AN 177.09 AN 
12.5 Q 15 Q 99.26 Q 
AN + R 12.5 AN 0 475 25 AN 177.09 AN 
12.5 R 30 R 98.28 R 
 To measure the amount of AN that passed through a Caco-2 monolayer in conjunction 
with Q, a similar method was used to that described for the transport of pure AN, modified to 
include Q in the transport experiment. Table 6 describes the experimental set-up for AN + Q 
studies. As with transport of AN alone, 12.5 µL of a 7.08 mM AN stock solution was used in 
transport medium. Additionally, 12.5 µL of a 3.97 mM Q stock solution made in 70% ethanol 
was added, yielding a concentration of 99.26 µM Q in each transwell insert. 
 For AN + R studies, we followed the method as described for the transport of pure AN, 
but modified to also include R in the transport medium. Similar to the AN + Q studies, 12.5 µL 
of R stock solution were added to the transport media. To maintain equal molarity of both Q and 
R, the stock solution of R was 3.93 mM, yielding a concentration of 98.28 µM R per transwell 
insert, as shown in Table 6. The distribution of experimental treatments in a 12 well plate is 
shown in Figure 7.  
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Figure 7: 12-Well plate experimental set-up diagram 
4.4 Quantification of artemisinin and flavonoid passage through the Caco-2 monolayer  
 Upon completion of each transport experiment, the medium from each well in every used 
well plate was immediately extracted with an equal volume of methylene chloride. The extracted 
samples were dried under N2 gas, resuspended in a known volume of methylene chloride, and a 
known aliquot was transferred to GC/MS vials. The amount of AN in each sample was 
quantified using the method of Weathers and Towler (2012). 
4.5 Statistical Analysis 
 There were three replicates of the AN studies, and two replicates each of the AN + Q and 
AN + R studies (Figure 7). To determine statistical significance of data between AN and AN + 
either Q or R, a Student’s T-Test was performed. 
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5.0 Results 
5.1 Lucifer Yellow Validation of Caco-2 Monolayers 
 To test the integrity of the Caco-2 monolayers, a single transwell insert was used in a 
representative Lucifer Yellow (LY) assay. The LY assay resulted in a percent LY rejection of 
75.52%. Although <80% this percentage was deemed sufficiently confluent to proceed with this 
preliminary transport study. Another transwell insert was used to control for any damage caused 
by exposure of the Caco-2 monolayers to 5% ethanol present in all studies. This LY assay 
resulted in an LY rejection of 83.60%, indicating no significant damage from exposure to 5% 
ethanol for 60 minutes and was consistent with the LY assay of the well lacking ethanol. The raw 
data for these LY assays are shown in Appendix F.  
5.2 Apical to Basolateral AN Transport 
First, AN ab transport was measured. The average concentration of AN on the 
basolateral side of transwell inserts for AN transport every fifteen minutes was not statistically 
different and ranged from an average of 0.4 µg/mL to 0.18 µg/mL at 60 minutes (Figure 8A). 
When Q was added with AN, there was not statistical difference from AN alone at each sampling 
time and the AN concentration at each time point ranged from 0.4 µg/mL to 0.3 µg/mL (Figure 
8B). Similarly, there was no statistical difference between AN alone and AN + R, in which the 
AN concentration at each sampling time ranged from 0.5 µg/mL to 0.6 µg/mL (Figure 8C). 
When Q was added to AN, its presence appeared to not only increase overall average AN 
concentration after 30 minutes, but seemed to result in more consistent AN passage across all 
time points (Figure 8B). Similarly, the presence of R also appeared to increase AN transport 
(Figure 8C). When the cumulative basolateral concentration of AN was measured, the rate of AN 
transport for the AN, AN + Q, and AN + R studies is shown in Figure 9. The orange and grey 
lines representing AN + Q and AN + R transport, respectively, indicate greater AN transport 
after 45 and 60 minutes than was seen in the blue line, which represented AN transport alone 
(Figure 9). However, only AN + R was significantly greater at 60 minutes. Indeed, the rate of 
AN transport ± Q or R was the same between 0 and 15 minutes (Figure 9). The transport of AN 
alone appeared to be bimodal; between 0 and 15 minutes the rate of change in AN concentration 
was 0.0203 µg mL-1 min-1, about four times faster than the rate of change, 0.0055 µg mL-1 min-1, 
between 15 and 60 minutes (Figure 10A).  
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Figure 8: Average Basolateral Concentration of AN ± Q or R over 60 minutes. A, AN alone; B, 
AN + Q; C, AN + R. 
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Figure 9: Cumulative AN concentration at 15-minute time points in all transport studies 
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Figure 10: Change in permeability rate of AN transport 
The appearance of bimodality may be influenced by the presence of an outlier at 15 minutes. 
Although when the outlying value was removed, bimodal AN transport was not as apparent, 
there was still a decline in the rate of change in AN concentration from 0.016 µg mL-1 min-1 
between 0 and 30 minutes to 0.0073 µg mL-1 min-1 from 30 to 60 minutes. (Figure 10B). 
5.2.1 Permeability Coefficient 
 Using the average total amount of AN transported across the Caco-2 monolayers over 60 
minutes, the permeability coefficient (Papp) for AN was calculated for AN, AN + Q, and AN + R 
studies using the equation shown in the methods. The permeability coefficient for AN alone was 
7.06 x 10-6 cm/s, which was not statistically different from that of AN + Q, which was 11.75 x 
10-6 cm/s. However, the permeability coefficient for AN + R, 12.65 x 10-6 cm/s, was statistically 
different from AN alone (Table 7). 
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Table 7: Permeability coefficient of AN for all studies 
Experimental Treatment Papp (cm/s) (x10-6) 
AN 7.06a 
AN + Q 11.75a 
AN + R 12.65b 
 
Both AN + Q and AN + R yielded greater Papp values than AN alone, with a percent change 
between AN and AN + Q of 66.43%, while the percent change between AN and AN + R was 
79.18%.   
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6.0 Discussion 
 In studying the transport across Caco-2 monolayers of AN alone, it was expected that a 
permeability coefficient Papp of approximately 30.4 x 10
-6 cm s-1 would result from a 60 minute 
transport study at 37º C, as reported by Augustijns et al. (1996). Such a result would indicate that 
AN was, as previously shown, successfully transported across Caco-2 monolayers through the 
passive transcellular pathway (Augustijns et al., 1996). Rather than using 24 mm transwell 
inserts used by Augustijns et al. (1996), this study used 12 mm inserts for culturing Caco-2 
monolayers, so there was a cross-sectional area of 1.22 cm2. However, because the permeability 
coefficient (Papp) was normalized to the growth surface area of the transwell, it was possible to 
compare the two results. Augustijns et al. (1996) reported that the Papp of AN was 30 cm/s (x 10
-
6).  The Papp for AN in this study was 7.06 cm/s (x 10
-6), about 24% of the earlier study. 
Similar to AN, Q is also transported across Caco-2 monolayers using the passive 
transcellular pathway (Walgren et al., 1998). Q also was shown to act synergistically with AN, 
so it was expected that AN transport across Caco-2 monolayers would be enhanced by the 
presence of Q (Hollman et al., 1996). As expected, when AN + Q was used in apical to 
basolateral transport studies, not only the rate, in terms of Papp, but the total amount of AN that 
crossed the Caco-2 monolayers increased, but neither value was statistically different from that 
of AN alone. 
In contrast to the passive transport of AN and Q, R was shown to be successfully 
transported across Caco-2 monolayers in a time- and dose-dependent manner using the active 
carrier-mediated transport (Zhang et al., 2013). In vitro experiments also showed that R was less 
bioavailable than Q after oral administration (Erlund et al., 2000). Rather, serosal levels of Q 
were shown to increase after ingestion of R, indicating that R, rather than being actively 
transported as was shown in vitro, is hydrolyzed into Q to facilitate transport through the 
intestinal lumen (Erlund et al., 2000). To our knowledge, R has not been specifically shown to 
act synergistically with AN. However, because it does travel across a Caco-2 monolayer and may 
be cleaved into Q to facilitate transport, R was also hypothesized to increase transport of AN 
across Caco-2 monolayers, with an increase in apical to basolateral Papp for AN. Though because 
R is less bioavailable any increase was anticipated to be less than that for AN + Q. However, the 
increase in Papp seen when R was added with AN was statistically different from that of AN 
alone, although the total amount of AN transported was not. This difference in rate of AN 
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transport was most evident between 45 and 60 minutes. Based on the observed permeability 
coefficients for AN + Q and AN + R, the results suggest that R may enhance AN transport.  
Q and R are related compounds, in that Q is the aglycone of R, yet only R significantly 
increased the rate AN transport. This suggested that the rutinose sugars in R may facilitate active 
transcellular transport of AN (Hollman et al., 1999). The apparent increase in Papp for AN may 
also be due to the transport of R through the active carrier-mediated pathway (Erlund et al., 
2000). It is unknown whether R was hydrolyzed to Q during incubation, as although samples 
were analyzed for R and Q, the two compounds are difficult to differentiate using GC/MS, as 
they have the same elution time and the same ion signature. 
 The Papp for AN alone could also be affected by the observed bimodality in AN transport. 
The permeability rate for AN alone between 0 and 15 minutes was 0.014 µg/mL greater than the 
rate between 15 and 60 minutes, a 25% increase compared to the later stage of the transport 
study.  
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7.0 Conclusions and Future Studies 
 In this study, flavonoids Q and R increased the rate of AN transport. Although from these 
data only AN + R was significantly different from AN transport alone, sample size was two, so it 
is possible that with a larger sample size, the AN + Q results could also be significant. Therefore, 
it is recommended that the studies of AN in combination with Q and R be further replicated to 
increase the overall sample size for statistical analysis.  
This in vitro study of AN transport suggested that flavonoids may affect pACT function 
by improving AN bioavailability. However, compounds such as other flavonoids, monoterpenes, 
and coumarins found in A. annua may also increase AN transport and should also be studied 
using apical to basolateral transport across Caco-2 monolayers. Additionally, ba studies with 
AN could provide insight into the mechanism of AN transport. In an ex vivo study by Weathers 
et al. (2014b), sucrose was found to have no effect on AN in the intestinal liquid fraction. 
However, sugars may affect AN transport in vitro, as seen in the rutionse sugars of R. Therefore, 
it is recommended that AN transport in the presence of sugars be studied using Caco-2 
monolayers. Specifically addition of either rhamnose or glucose or both should be included to 
determine their affect on AN + Q transport. 
Another variable that should be examined is that of concentration. In contrast to the 
passive transport of AN and Q, R was shown to be successfully transported across Caco-2 
monolayers in a time- and dose-dependent manner through active carrier-mediated transport 
(Zhang et al., 2013). Because R significantly increased AN transport at 98.28 µM, it is 
recommended that different concentrations of R be studied to determine whether higher or lower 
concentrations alter the assistance of AN transport across Caco-2 monolayers. Additionally, a 
longer period of study for transport experiments and/or increased sampling of the basolateral 
media is recommended to determine the effect of time in Q and R assistance of AN transport. 
For the purposes of examining the effects of flavonoids on the bioavailability of AN, a 
model system was created with Caco-2 cells, which mimicked the human intestinal epithelium, a 
critical component in this and future transport studies. In doing this, pertinent standard operating 
procedures (SOP) were developed (Appendix A-G). These SOPs were specific to transport 
studies using Caco-2 cells on 12 mm transwell inserts and were developed through both research 
and experimental trials. Additionally, several protocols are recommended for future work with 
this model system. When culturing cells prior to transwell seeding, EMEM media with 20% FBS 
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is recommended to accelerate cell proliferation. In contrast, when seeding and incubating Caco-2 
monolayers on transwell inserts, EMEM media with 10% FBS is recommended to promote cell 
differentiation. Once seeded onto transwell inserts, Caco-2 monolayers should be incubated for a 
minimum of three weeks before transport studies are performed. This allows monolayers to 
become fully confluent, as a three-week incubation yields an average percent LY rejection of 
80%. During this incubation period, minimal transport of the cultures is recommended to reduce 
the risk of contamination. With these recommendations, a successful model system for AN 
transport studies can be created. 
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Appendices 
Appendix A: Treatment algorithm for malaria (CDC, 2012). 
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Appendix B: Standard Operating Procedure for Lucifer Yellow Assay 
This SOP was modified from the Corning HTS Transwell-96 Permeable Support Protocols 
for Drug Transport, available from Corning, Inc. Lucifer Yellow (LY) is a fluorescent dye with 
low permeability that can travel across a cell monolayer only via paracellular diffusion, meaning 
diffusion through the gaps between cells. Thus, LY is not able to pass through when the cells 
have tight junctions, i.e., when the monolayer is fully confluent. A Papp between 5 and 12 nm/s 
or a 90% LY rejection is indicative of well-established monolayers. The following steps are used 
to prepare and execute a LY Rejection Assay (calculating either Papp, Percent Rejection, or 
both) using Caco-2 monolayers on 12 mm, 0.4 µm transwell inserts and 96-well fluorescent 
reader plates. 
 
1. Make a solution of 1% DMSO in PBS.  
2. Prewarm all reagents before beginning assay: 
 PBS 
 1% DMSO in PBS 
3. Aliquot 1.88 mL of 1% DMSO in PBS to each well of a new receiver plate and place in 
37⁰C incubator. 
4. Remove transwell plate from incubator. 
5. Wash each transwell insert 3 times with prewarmed PBS (no DMSO). 
Note: Be sure to wash the monolayers gently in order to preserve monolayer integrity. 
Wash monolayers until the liquid discarded is no longer pink. 
6. Add 600 µL of 60uM LY solution in PBS 1% DMSO to each well of the transwell insert. 
7. Remove prepared receiver plate from the incubator. 
8. Place transwell insert into receiver plate of step 4. 
9. Incubate plate at 37⁰C, 5% CO₂ for 1 hour. 
10. During the incubation period, make the dilutions for a standard curve. 
 Make LY solutions in PBS 1% DMSO. 
 Make five 1:3 dilutions. Follow the table below to create each solution. Place each 
solution directly into the black reader plate and gently pipet the solution up and down 
to mix. 
Dilution 
Number 
60µM LY 
Solution (µL) 
PBS 1% 
DMSO 
Concentration of LY 
Solution (µM) 
Absolute Amount LY 
(nanomoles) 
1 200 0 60 12 
2 66.67 133.33 20 4 
3 22.23 177.78 6.7 1.33 
4 7.41 192.59 2.23 0.44 
5 2.47 197.53 0.74 0.15 
 
11. Once the incubation period is complete, pipet the entire contents of each receiver plate 
(basolateral side) and transwell insert (apical side) into respective containers. Record the 
volumes removed, as they will be used for concentration calculations later. 
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12. Transfer 200 µL of medium from the receiver plate(s) (basolateral side) into a 
corresponding well of a solid black plate. 
Note: It is very helpful to make a table of the contents of each well in the plate, as 
it is easy to lose track. 
13. Transfer 50 µL of medium from the transwell insert (apical side) into a corresponding 
well of the solid black plate. Add 50 µL of PBS 1% DMSO to any well into which apical 
medium was added. 
14. Read plates in an appropriate fluorescent reader (Excitation/Emission wavelength 480 
(20) nm/530 (20) nm). 
15. In Excel or similar, graph the standard curve in absolute amounts versus RFU value. On 
the graph, insert a linear line of best fit and display the R2-value and equation. Using the 
equation for the line, calculate the absolute amounts of LY for all basolateral and apical 
medium. Using the absolute amount and the volumes collected in step 11 to calculate the 
molarity of LY from apical and basolateral sides. 
Note: Remember that the apical medium placed in the reader plate is a 1:2 
dilution, so multiply by 2 to get corrected RFU values for wells containing apical 
medium. 
16. Using the calculated final concentration on basolateral side(s) calculate the Papp.  
17. Using the RFU values from apical and basolateral sides, calculate % LY Rejection 
Note: Remember that the apical medium placed in the reader plate is a 1:2 
dilution, so multiply by 2 to get corrected RFU values for wells containing apical 
medium. 
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Appendix C: Fluorescence Plate Reader Protocol 
1. Place the well plate with sample in the fluorescent plate reader. You do not need to leave 
the lid on the plate for this. 
2. Click on the Wallac-1420 icon 
3. Click define plate map 
4. Find protocol: Wobbe Lab, PW MQP Group 
5. Instrument control tab: 
a. Define plate map. Click and highlight and choose empty or measured. This is 
done by rows. 
6. Click next twice, then finish to start reading the plate. The live display tab shows a color 
legend as the plate is being read. Once the reading is complete, click the latest assay run 
button. The plate tab gives an excel chart of the numerical readings. To export the file to 
the desktop, click file  export. Click the shortcut to user data  Weathers. Either create 
a folder use a premade folder, then save the exported plate data into the folder. The file 
then exports as an excel file. Because the computer is not connected to a network, save 
the exported excel to a thumb drive to take it out of the lab. 
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Appendix D: Solubility of AN, Quercetin, and Rutin in Ethanol 
 To test the solubility of AN, Q, and R in ethanol, stock solutions of each compound were 
made in ethanol. An aliquot of each respective stock solution was added to a test tube and diluted 
with PBS. The diluted samples were then extracted with methylene chloride for analysis with 
Gas Chromatography/Mass Spectrometry (GC/MS). The exact protocol for this solubility study 
was as follows. 
1. Test tubes containing 200 µg AN, 200 µg Q, and 100 µg R, respectively, were brought up in 
ethanol to make 1 µg/µL stock solutions. 
 200 µL ethanol added to each of the AN and Q samples, 100 µL ethanol added to R 
sample. 
2. Aliquots were taken from each stock solution and added to new test tubes. The amount added 
to each tube was equal to the amount of stock solution needed to make enough dissolved 
compound in PBS for use on 4 transwells. 
Table 1: Contents of solubility study samples 
Replicate Artemisinin Samples Quercetin Samples Rutin Samples 
1 120 µL AN stock 
solution 
2 mL PBS 
24 µL Q stock  solution 
2 mL PBS 
24 µL R stock  solution 
2 mL PBS 
2 120 µL AN stock 
solution 
2 mL PBS 
24 µL Q stock  solution 
2 mL PBS 
24 µL R stock  solution 
2 mL water 
3 120 µL AN stock 
solution 
24 µL Q stock solution 24 µL R stock solution 
 
3. Two replicates of each diluted stock solution were made. As a control, undiluted stock 
solution was also extracted for GC/MS analysis. 
4. To extract each diluted sample, 2 mL of methylene chloride was added to each tube. 1 mL of 
methylene chloride was added to the tubes containing undiluted stock solutions. 
5. The methylene chloride from each extraction was transferred to new test tubes using Pasteur 
pipets. 
6. The tubes containing methylene chloride extractions were dried down under nitrogen gas. 
The dried extractions were then used for GC/MS analysis. 
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Appendix E: Cell Counting Format and Example 
 Cell counting is essential for determining the volume of cell suspension to be seeded onto 
each transwell insert for use in drug transport studies. To count cells, the cells must first be 
trypsinized from the culture surface, centrifuged, and resuspended in culture medium. Using an 
aliquot of the resuspended culture, a solution of 50 µL trypan blue and 50 µL cell suspension is 
created in an Eppendorf tube. This solution is then pipetted onto a hemocytometer. The 
hemocytometer is then examined under a microscope. Hemocytometers consist of nine 1 mm2 
squares, each of which is divided into smaller squares of 0.2 mm2 each. To count cells, the 
entirety of at least one large 1 mm2 square must be counted. If 100 total cells are not visible in 
this square, other squares are counted until the number of total cells is at least 100. Each large 
square must be counted in its entirety, even if the minimum count of 100 is reached before the 
square has been fully counted. 
 To determine the number of live cells counted, the number of dead cells, identified by 
their blue color, is subtracted from the number of total cells counted. If more than one square 
was used to reach the total number of cells, the number of live cells counted is divided by the 
number of squares used for the count, giving the number of live cells/mm2. This number is then 
converted into live cells/mL using the following formula: 
 
𝐿𝑖𝑣𝑒 𝑐𝑒𝑙𝑙𝑠 𝑚𝐿⁄ =  
(𝐿𝑖𝑣𝑒 𝑐𝑒𝑙𝑙𝑠/𝑚𝑚2)
1 𝑥 10−4 𝑚𝐿
∗ 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 𝑢𝑠𝑒𝑑 𝑓𝑜𝑟 𝑐𝑜𝑢𝑛𝑡𝑖𝑛𝑔 
 
In this formula, 1 x 10-4 mL is the volume of one 1 mm2 square and the dilution factor is 2, as the 
counting solution was made with 1:1 trypan blue and cell suspension. The concentration of live 
cells per milliliter is then multiplied by the volume in milliliters of cell suspension available 
(Freshney, 1994). 
 Using the calculated cells per milliliter, the number of transwells that can be seeded from 
the volume of cell suspension available can be calculated by dividing the cells/mL by 300,000, 
the number of cells needed to seed a 12 mm diameter transwell insert. Conversely, to calculate 
the volume of cell suspension needed to seed each transwell, the number of cells needed, 
300,000, is divided by the calculated cells/mL. 
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Appendix F: Lucifer Yellow Results & Analysis 
The first Lucifer Yellow (LY) assay performed on a single transwell insert was carried out using 
the Corning Transwell Protocols for 96-well plates. The standard curve results are shown in 
Table 1 and Figures 1 and 2. 
Table 1: Standard curve concentrations and fluorescence readings for Lucifer Yellow 
Concentration of 
LY (µM) 
Average Normalized 
RFU 
60.00 222541 
20.00 81893 
6.67 89761 
1.00 18616 
0.33 6237 
0.11 5588 
 
 
Figure 1: High Lucifer Yellow Standard Curve 
 
 
Figure 2: Low Lucifer Yellow Standard Curve 
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The data points for each concentration did not show a strong linear trend (Figure 1, 
Figure 2). Table 2 shows the fluorescence readings from the apical and basolateral sides one hour 
after addition of 60 µM LY in PBS 1% DMSO. 
Table 2: Apical and Basolateral Transwell Fluorescence Readings 
 Apical RFU Basolateral RFU 
Replicate 1 68518 20478 
Replicate 2 69862 21074 
Replicate 3 71402 20603 
Replicate 4 62322 23393 
Average 68026 21387 
 
Using the fluorescence readings shown in Table 2, percent LY rejection was calculated using the 
formula outlined in the literature review. The resultant % LY rejection value was 68.56%, which 
did not meet the 80% threshold required for a confluent monolayer in the transwell insert. 
 Before drug transport studies could be carried out, an LY assay was performed on one of 
the nine transwell insert to determine whether or not the Caco-2 monolayers were sufficiently 
confluent for use in transport studies. This LY assay was performed using the LY SOP. Table 3 
shows the data used to create the LY standard curve (Figure 3). 
Table 3: Amount of LY and Fluorescence Readings for LY Assay 3/17/14 
Absolute Amt. of LY (nanomoles) Absorbance (RFU) 
12 419629 
4 153281 
1.33 53102 
0.44 17767 
0.15 6864 
 
 
Figure 3: LY Standard Curve for LY Assay 3/17/14 
 
Using this standard curve, the absolute amount of LY on apical and basolateral sides after 60 
minute incubation was calculated (Table 4, Table 5). 
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Table 4: Apical Fluorescence Reading, Amount of LY, and Concentration of LY for LY Assay 
3/17/14 
Replicate 
Absorbance 
(RFU) 
Normalized 
Absorbance (RFU) 
Absolute Amount of 
LY (nanomoles) 
1 64098 126467 3.53 
2 48702 95675 2.64 
3 60393 119057 3.32 
4 64954 128179 4.00 
5 61659 121589 3.39 
6 63895 126061 3.52 
 
Table 5: Basolateral Fluorescence Reading, Amount of LY, and Concentration of LY for LY 
Assay 3/17/14 
Replicate 
Normalized 
Absorbance 
(RFU) 
Absolute 
Amount of LY 
(moles) 
Concentration 
of LY (µM) 
1 27685 0.69 3.43 
2 29362 0.73 3.67 
3 29495 0.74 3.69 
4 29054 0.73 3.63 
5 30046 0.75 3.77 
6 31547 29818 0.75 
 
Using the calculated concentrations, the permeability coefficient (Papp) for LY was determined 
using the formula outlined in the literature review. The calculated permeability coefficient was 
2.7 nm/s. The calculated percent LY rejection was 75.53%. Based on these values, the remaining 
Caco-2 monolayers were deemed sufficiently confluent to proceed with experimentation. 
 To control for cell damage due to exposure to 5% ethanol during experimentation, one 
transwell insert was incubated with 5% ethanol in PBS for 60 minutes, after which an LY assay 
was performed. As before, the amount and concentration of LY on apical and basolateral sides 
after 60 minutes were calculated (Table 6, Table 7). 
Table 6: Apical Fluorescence Reading, Amount of LY, and Concentration of LY for Ethanol 
Control LY Assay 3/17/14 
Replicate 
Absorbance 
(RFU) 
Normalized 
Absorbance (RFU) 
Absolute Amount of 
LY (nanomoles) 
1 64229 126729 3.54 
2 65946 130163 3.64 
3 65591 129453 3.62 
4 65560 129391 3.61 
5 64858 127987 3.57 
6 62898 124067 3.46 
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Table 7: Basolateral Fluorescence Reading, Amount of LY, and Concentration of LY for LY 
Assay 3/17/14 
Replicate 
Absorbance 
(RFU) 
Normalized 
Absorbance 
(RFU) 
Absolute 
Amount of LY 
(nanomoles) 
1 22458 20729 0.49 
2 22388 20659 0.48 
3 22523 20794 0.49 
4 22872 21143 0.50 
5 22926 21197 0.50 
6 22716 20987 0.49 
 
These results yielded a Papp of 1.7 nm/s and a percent LY rejection of 83.60%, indicating that the 
Caco-2 monolayer had not been damaged by ethanol exposure. 
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Appendix G: GC/MS Raw Data 
 When all samples from apical to basolateral transport studies were collected and dried 
with N2 gas, the samples were analyzed using Gas Chromatography/Mass Spectrometry 
(GC/MS) (Table 1, Table 2, Table 3). 
Table 1: AN Transport 
Vial µg AN/vial 
Concentration of AN (µg/mL) 
in Transport Media 
AN1 0 Apical 19.99 39.98 
AN2 0 Apical 20.78 41.57 
AN3 0 Apical 17.09 34.18 
AN1 15 Basolateral 0.33 0.22 
AN2 15 Basolateral 0.59 0.39 
AN3 15 Basolateral 0.94 0.62 
AN1 30 Basolateral 0.15 0.10 
AN2 30 Basolateral 0.12 0.08 
AN3 30 Basolateral 0.14 0.09 
AN1 45 Basolateral 0.14 0.09 
AN2 45 Basolateral 0.08 0.05 
AN3 45 Basolateral 0 0 
AN1 60 Basolateral 0.32 0.21 
AN2 60 Basolateral 0.18 0.12 
AN3 60 Basolateral 0.25 0.17 
AN1 60 Apical 2.32 4.63 
AN2 60 Apical 2.73 5.46 
AN3 60 Apical 3.28 6.55 
 
Table 2: AN + Q Transport 
Vial µg AN/vial 
Concentration of AN (µg/mL) 
in Transport Media 
AN + Q1 0 Apical 13.91 27.82 
AN + Q2 0 Apical 18.82 37.64 
AN + Q1 15 Basolateral 0.60 0.40 
AN + Q2 15 Basolateral 0.36 0.24 
AN + Q1 30 Basolateral 0.42 0.28 
AN + Q2 30 Basolateral 0.32 0.22 
AN + Q1 45 Basolateral 0.21 0.14 
AN + Q2 45 Basolateral 0.41 0.27 
AN + Q1 60 Basolateral 0.45 0.30 
AN + Q2 60 Basolateral 0.20 0.14 
AN + Q1 60 Apical 4.15 8.29 
AN + Q2 60 Apical 4.04 8.08 
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Table 3: AN + R Transport 
Vial µg AN/vial 
Concentration of AN (µg/mL) 
in Transport Media 
AN + R1 0 Apical 16.97 33.94 
AN + R2 0 Apical 15.85 31.69 
AN + R1 15 Basolateral 0.50 0.33 
AN + R2 15 Basolateral 0.57 0.38 
AN + R1 30 Basolateral 0.71 0.47 
AN + R2 30 Basolateral 0.16 0.11 
AN + R1 45 Basolateral 0.12 0.08 
AN + R2 45 Basolateral 0.11 0.08 
AN + R1 60 Basolateral 0.50 0.33 
AN + R2 60 Basolateral 0.69 0.46 
AN + R1 60 Apical 9.15 18.30 
AN + R2 60 Apical 2.44 4.89 
 
Table 4: Q and R Data 
Experimental Treatment Sampling Time µg/vial (Q equivalents) 
AN + Q 0 Apical 4.80 
60 Apical 2.24 
60 Basolateral 0.48 
AN + R 0 Apical 0.41 
60 Apical 12.83 
60 Basolateral 1.15 
 
 
 
